[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BE2012C036I2 - - Google Patents

Download PDF

Info

Publication number
BE2012C036I2
BE2012C036I2 BE2012C036C BE2012C036C BE2012C036I2 BE 2012C036 I2 BE2012C036 I2 BE 2012C036I2 BE 2012C036 C BE2012C036 C BE 2012C036C BE 2012C036 C BE2012C036 C BE 2012C036C BE 2012C036 I2 BE2012C036 I2 BE 2012C036I2
Authority
BE
Belgium
Application number
BE2012C036C
Other languages
French (fr)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153696&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2012C036(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of BE2012C036I2 publication Critical patent/BE2012C036I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BE2012C036C 1999-11-05 2012-08-09 BE2012C036I2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP99402759 1999-11-05
EP99402877 1999-11-19
PCT/GB2000/004181 WO2001032651A1 (en) 1999-11-05 2000-11-01 Quinazoline derivatives as vegf inhibitors

Publications (1)

Publication Number Publication Date
BE2012C036I2 true BE2012C036I2 (hu) 2019-12-11

Family

ID=26153696

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2012C036C BE2012C036I2 (hu) 1999-11-05 2012-08-09

Country Status (36)

Country Link
US (9) US7173038B1 (hu)
EP (2) EP1244647B1 (hu)
JP (1) JP3522727B2 (hu)
KR (3) KR100849151B1 (hu)
CN (2) CN101219145A (hu)
AR (1) AR033499A1 (hu)
AT (2) ATE398120T1 (hu)
AU (1) AU769222B2 (hu)
BE (1) BE2012C036I2 (hu)
BG (1) BG65861B1 (hu)
BR (2) BR0015203A (hu)
CA (1) CA2389767C (hu)
CY (3) CY1106166T1 (hu)
CZ (1) CZ301689B6 (hu)
DE (2) DE60039206D1 (hu)
DK (2) DK1676845T3 (hu)
EE (1) EE05330B1 (hu)
ES (2) ES2265998T3 (hu)
FR (1) FR12C0048I2 (hu)
HK (2) HK1049664B (hu)
HU (1) HU229414B1 (hu)
IL (2) IL149034A0 (hu)
IS (2) IS2284B (hu)
LU (1) LU92057I2 (hu)
MX (1) MXPA02004366A (hu)
NO (2) NO322298B1 (hu)
NZ (1) NZ518028A (hu)
PL (1) PL203782B1 (hu)
PT (2) PT1676845E (hu)
RU (1) RU2291868C2 (hu)
SI (2) SI1676845T1 (hu)
SK (1) SK287401B6 (hu)
TW (1) TWI287540B (hu)
UA (1) UA72946C2 (hu)
WO (1) WO2001032651A1 (hu)
ZA (1) ZA200202775B (hu)

Families Citing this family (223)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
ATE398120T1 (de) * 1999-11-05 2008-07-15 Astrazeneca Ab Neue quinazolin-derivate
GB0008269D0 (en) * 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
GB0126879D0 (en) * 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
ATE347908T1 (de) * 2002-01-29 2007-01-15 Vlaams Interuniv Inst Biotech Vorbeugung von gewebeadhäsion
NZ534171A (en) 2002-02-01 2007-06-29 Astrazeneca Ab Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
WO2004006846A2 (en) * 2002-07-15 2004-01-22 Exelixis, Inc. Receptor-type kinase modulators and methods of use
WO2004014383A1 (en) * 2002-08-09 2004-02-19 Astrazeneca Ab Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
DE10237423A1 (de) 2002-08-16 2004-02-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von LCK-Inhibitoren für die Behandlung von immunologischen Erkrankungen
GB0223380D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
CA2503371C (en) 2002-11-04 2011-01-11 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors
CA2514227C (en) * 2003-02-13 2011-08-09 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
AU2004255022B2 (en) * 2003-07-10 2007-08-23 Astrazeneca Ab Use of the quinazoline derivative ZD6474 combined with platinum compounds and optionally ionising radiation in the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0316176D0 (en) * 2003-07-10 2003-08-13 Astrazeneca Ab Combination therapy
MEP31408A (en) 2003-07-18 2010-10-10 Abgenix Inc Specific binding agents to hepatocyte growth factor
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
GB0318423D0 (en) * 2003-08-06 2003-09-10 Astrazeneca Ab Chemical compounds
SI1667991T1 (sl) * 2003-09-16 2008-10-31 Astrazeneca Ab Kinazolinski derivati kot inhibitorji tirozin kinaze
CA2540008A1 (en) * 2003-09-25 2005-04-07 Astrazeneca Ab Quinazoline derivatives
GB0330002D0 (en) * 2003-12-24 2004-01-28 Astrazeneca Ab Quinazoline derivatives
ES2315834T3 (es) 2004-02-03 2009-04-01 Astrazeneca Ab Derivados de quinazolina.
GB0421438D0 (en) * 2004-09-27 2004-10-27 Astrazeneca Ab Combination therapy
GB0411378D0 (en) * 2004-05-21 2004-06-23 Astrazeneca Ab Pharmaceutical compositions
EP1765313A2 (en) * 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
KR20070072543A (ko) * 2004-09-27 2007-07-04 아스트라제네카 아베 Ｚｄ6474 및 이마티닙을 포함하는 병합법
GB0424339D0 (en) * 2004-11-03 2004-12-08 Astrazeneca Ab Combination therapy
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
US7973140B2 (en) 2004-12-21 2011-07-05 Medimmune Limited Antibodies directed to angiopoietin-2 and uses thereof
CN1854130B (zh) * 2005-04-15 2011-04-20 中国医学科学院药物研究所 喹唑啉衍生物、及其制法和药物组合物与用途
CN102942522A (zh) 2005-05-18 2013-02-27 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
GB0519878D0 (en) * 2005-09-30 2005-11-09 Astrazeneca Ab Chemical compound
AU2011203358B2 (en) * 2005-09-30 2013-05-30 Genzyme Corporation Chemical process
US20080108664A1 (en) 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
JP2009526050A (ja) 2006-02-10 2009-07-16 アムジエン・インコーポレーテツド Ａｍｇ７０６の水和物形態
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
WO2007124288A1 (en) 2006-04-19 2007-11-01 Novartis Ag Indazole compounds and methods for inhibition of cdc7
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
CA2659971A1 (en) 2006-08-04 2008-02-07 Takeda Pharmaceutical Company Limited Fused heterocyclic derivative and use thereof
PT2057156T (pt) 2006-08-23 2017-05-04 Kudos Pharm Ltd Derivados de 2-metilmorfolina pirido-, pirazo- e pirimidopirimidina como inibidores de mtor
EP2066353B1 (en) * 2006-09-29 2013-01-02 AstraZeneca AB Combination of zd6474 and bevacizumab for cancer therapy
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
JP5528807B2 (ja) 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
WO2008046242A1 (fr) * 2006-10-16 2008-04-24 Institute Of Mataria Medica, Chinese Academy Of Medical Sciences Nouveaux dérivés quinazolines, leurs procédés de préparation et leurs utilisations
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
CA2672438A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Substituted heterocycles and methods of use
WO2008086014A2 (en) 2007-01-09 2008-07-17 Amgen Inc. Bis-aryl amide derivatives useful for the treatment of cancer
MX2009007610A (es) 2007-02-06 2009-07-24 Boehringer Ingelheim Int Heterociclicos biciclicos, medicamentos que contienen estos compuestos, su utilizacion y procedimientos para su preparacion.
US20080190689A1 (en) * 2007-02-12 2008-08-14 Ballard Ebbin C Inserts for engine exhaust systems
EP2114898A2 (en) 2007-02-16 2009-11-11 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-met inhibitors
WO2008114819A1 (ja) 2007-03-20 2008-09-25 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
PE20081887A1 (es) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
US8914063B2 (en) 2007-05-15 2014-12-16 Lg Electronics Inc. Mobile terminal equipped with mode setting key and method of controlling the mobile terminal
AR066845A1 (es) 2007-06-05 2009-09-16 Takeda Pharmaceutical Derivados de triazolopiridina e imidazopiridina una composicion farmaceutica que los comprende y su uso en la preparacion de un medicamento para el tratamiento del cancer
JP5718640B2 (ja) 2007-08-21 2015-05-13 アムジエン・インコーポレーテツド ヒトｃ−ｆｍｓ抗原結合性タンパク質
US8324395B2 (en) 2007-08-23 2012-12-04 Takeda Pharmaceutical Company Limited Heterocyclic compound and use thereof
UY31384A1 (es) 2007-10-11 2009-05-29 Novedosos compuestos heterociclicos para la inhibicion de la proteina quinasa b
PT2690101E (pt) 2007-12-19 2015-10-08 Genentech Inc 5-anilinoimidazopiridinas e métodos de utilização
PE20091523A1 (es) 2007-12-20 2009-10-29 Novartis Ag Derivados de tiazol como inhibidores de la enzima fosfatidilinositol 3-cinasa (pi3k)
JP5710269B2 (ja) 2007-12-21 2015-04-30 ジェネンテック， インコーポレイテッド アザインドリジン類と使用方法
WO2009094210A1 (en) * 2008-01-22 2009-07-30 Concert Pharmaceuticals Inc. Vandetanib derivatives
BRPI0907916A2 (pt) 2008-02-07 2015-07-28 Boehringer Ingelheim Int Heterociclos espirociclos, medicamentos contendo esses compostos, e processos para preparar os mesmos
BRPI0908100A2 (pt) * 2008-02-21 2015-10-06 Astrazeneca Ab produto combinação, uso de um composto, e, método de tratar câncer
BRPI0912170A2 (pt) 2008-05-13 2015-10-13 Astrazeneca Ab composto, forma a, processo para a preparação da mesma, composição farmacêutica, uso de um composto, e, método para tratar um câncer em um animal de sangue quente
US20110200612A1 (en) 2008-06-30 2011-08-18 Michael Schuster Treatment of eye diseases and excessive neovascularization using combined therapy
CA2733153C (en) 2008-08-08 2016-11-08 Boehringer Ingelheim International Gmbh Cyclohexyloxy substituted heterocycles, pharmaceutical compositions containing these compounds and processes for preparing them
JP5778577B2 (ja) 2008-09-19 2015-09-16 メディミューン，エルエルシー Ｄｌｌ４に対する抗体およびその使用
WO2010064611A1 (ja) 2008-12-01 2010-06-10 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
US20110053923A1 (en) 2008-12-22 2011-03-03 Astrazeneca Chemical compounds 610
WO2010072740A2 (en) 2008-12-23 2010-07-01 Astrazeneca Ab TARGETED BINDING AGENTS DIRECTED TO α5β1 AND USES THEREOF
IL295601B2 (en) 2009-02-05 2024-11-01 Immunogen Inc History of benzodiazepines and processes for their preparation
EP2406258B1 (en) 2009-03-13 2014-12-03 Cellzome Limited PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
WO2010118986A1 (en) 2009-04-14 2010-10-21 Cellzome Limited Fluoro substituted pyrimidine compounds as jak3 inhibitors
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
WO2011029807A1 (en) 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors
EP2491039A1 (en) 2009-10-20 2012-08-29 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
CN102070608A (zh) * 2009-11-19 2011-05-25 天津药物研究院 4-取代苯胺基-7-取代烷氧基-喹唑啉衍生物、其制备方法和用途
BR112012012465B1 (pt) 2009-11-24 2023-03-14 Medimmune Limited Anticorpo isolado ou fragmento de ligação do mesmo que se liga especificamente a b7-h1 humano, composição compreendendo o mesmo e usos
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
EP2533810B1 (en) 2010-02-10 2016-10-12 ImmunoGen, Inc. Cd20 antibodies and uses thereof
ES2535116T3 (es) 2010-03-04 2015-05-05 Cellzome Limited Derivados de urea sustituida con morfolino como inhibidores de mtor
EP2566867A1 (en) 2010-04-30 2013-03-13 Cellzome Limited Pyrazole compounds as jak inhibitors
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2011161217A2 (en) 2010-06-23 2011-12-29 Palacký University in Olomouc Targeting of vegfr2
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
JP2013534233A (ja) 2010-08-20 2013-09-02 セルゾーム リミティッド 選択的ｊａｋ阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
JP2013537966A (ja) 2010-08-31 2013-10-07 ジェネンテック， インコーポレイテッド バイオマーカー及び治療の方法
CN103298794A (zh) 2010-11-09 2013-09-11 塞尔卓姆有限公司 作为tyk2抑制剂的吡啶化合物及其氮杂类似物
CN102532103B (zh) * 2010-12-20 2014-07-09 天津药物研究院 喹唑啉芳基脲衍生物及其制备方法和用途
MX343706B (es) 2011-01-31 2016-11-18 Novartis Ag Derivados heterocíclicos novedosos.
ES2717657T3 (es) 2011-02-15 2019-06-24 Immunogen Inc Métodos para la preparación de conjugados
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
JP5647374B2 (ja) 2011-03-23 2014-12-24 アムジエン・インコーポレーテツド Ｃｄｋ４／６およびｆｌｔ３の縮合三環系二重阻害剤
US20140163023A1 (en) 2011-04-04 2014-06-12 Cellzome Limited Dihydropyrrolo pyrimidine derivatives as mtor inhibitors
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
CN103781780B (zh) 2011-07-28 2015-11-25 赛尔佐姆有限公司 作为jak抑制剂的杂环基嘧啶类似物
WO2013017479A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
US9745288B2 (en) 2011-08-16 2017-08-29 Indiana University Research And Technology Corporation Compounds and methods for treating cancer by inhibiting the urokinase receptor
EP2760863A1 (en) 2011-09-20 2014-08-06 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
AU2012311458B2 (en) 2011-09-21 2016-02-04 Cellzome Limited Morpholino substituted urea or carbamate derivatives as mTOR inhibitors
AU2012320465B2 (en) 2011-10-07 2016-03-03 Cellzome Limited Morpholino substituted bicyclic pyrimidine urea or carbamate derivatives as mTOR inhibitors
BR112014009890A2 (pt) 2011-10-28 2020-10-27 Novartis Ag derivados de purina e seu uso no tratamento de doença
BR112014015723A8 (pt) 2011-12-23 2017-07-04 Cellzome Ltd derivados de pirimidino-2,4-diamina como inibidores da quinase
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
DK2859017T3 (da) 2012-06-08 2019-05-13 Sutro Biopharma Inc Antistoffer omfattrende stedsspecifikke ikke-naturlige aminosyrerester, fremgangsmåder til fremstilling heraf og fremgangsmåder til anvendelse heraf
ES2611788T3 (es) 2012-06-26 2017-05-10 Sutro Biopharma, Inc. Proteínas de Fc modificadas que comprenden residuos de aminoácidos no naturales específicos del sitio, conjugados de las mismas, métodos para su preparación y métodos para su uso
JP2015524826A (ja) 2012-08-17 2015-08-27 キャンサー・セラピューティクス・シーアールシー・ピーティーワイ・リミテッド Ｖｅｇｆｒ３阻害剤
EP2887965A1 (en) 2012-08-22 2015-07-01 ImmunoGen, Inc. Cytotoxic benzodiazepine derivatives
EP2890696A1 (en) 2012-08-29 2015-07-08 Amgen, Inc. Quinazolinone compounds and derivatives thereof
KR102182800B1 (ko) 2012-08-31 2020-11-25 서트로 바이오파마, 인크. 아지도 기를 포함하는 변형된 아미노산
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014045101A1 (en) 2012-09-21 2014-03-27 Cellzome Gmbh Tetrazolo quinoxaline derivatives as tankyrase inhibitors
US20150259649A1 (en) 2012-11-08 2015-09-17 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto
CA2900097A1 (en) 2013-02-22 2014-08-28 F. Hoffmann-La Roche Ag Methods of treating cancer and preventing drug resistance
US9901647B2 (en) 2013-02-28 2018-02-27 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
WO2014134483A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
JP2016510751A (ja) 2013-03-06 2016-04-11 ジェネンテック， インコーポレイテッド 抗がん剤耐性を治療及び予防する方法
CA2905070A1 (en) 2013-03-14 2014-09-25 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
WO2014144850A1 (en) 2013-03-15 2014-09-18 Genentech, Inc. Methods of treating cancer and preventing cancer drug resistance
WO2014194030A2 (en) 2013-05-31 2014-12-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
EP3019522B1 (en) 2013-07-10 2017-12-13 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
JP6612232B2 (ja) 2013-08-28 2019-11-27 クラウン バイオサイエンス インコーポレイテッド（タイカン） 対象のマルチキナーゼ阻害剤に対する応答性を予測する遺伝子発現シグネチャ、及びその使用
CN103483276B (zh) * 2013-09-22 2018-04-17 南京恒道医药科技有限公司 一种凡德他尼杂质的制备方法
EP3055298B1 (en) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Modified amino acids comprising tetrazine functional groups, methods of preparation, and methods of their use
PL3076969T3 (pl) 2013-12-06 2022-01-17 Novartis Ag Schemat dawkowania selektywnego inhibitora 3-kinazy fosfatydynozytolu alfa-izoformy
KR20160137599A (ko) 2014-03-24 2016-11-30 제넨테크, 인크. C-met 길항제로의 암 치료 및 이것과 hgf 발현과의 상관관계
ES2887474T3 (es) 2015-01-08 2021-12-22 Univ Leland Stanford Junior Factores y células que proporcionan inducción de hueso, médula ósea y cartílago
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
CN106317022A (zh) * 2015-06-25 2017-01-11 中美华世通生物医药科技（武汉）有限公司 化合物的制备方法和用途
RU2018119085A (ru) 2015-11-02 2019-12-04 Новартис Аг Схема введения ингибитора фосфатидилинозитол-3-киназы
CN105254614B (zh) * 2015-11-16 2017-08-15 山东罗欣药业集团股份有限公司 一种凡德他尼化合物的合成方法
JP7306827B2 (ja) 2016-01-27 2023-07-11 ストロ バイオファーマ インコーポレーテッド 抗ｃｄ７４抗体コンジュゲート、抗ｃｄ７４抗体コンジュゲートを含む組成物および抗ｃｄ７４抗体コンジュゲートを使用する方法
EP3414330A4 (en) 2016-02-08 2019-07-03 Vitrisa Therapeutics, Inc. COMPOSITIONS WITH IMPROVED INTRAVITREAL HALF TIME AND USES THEREOF
CN106317039A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 一种含噻吩磺酰胺结构的乙氧苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106349230A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一种含硝基噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂及用途
CN106349231A (zh) * 2016-08-09 2017-01-25 浙江医药高等专科学校 一类含卤代噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106317040A (zh) * 2016-08-09 2017-01-11 浙江医药高等专科学校 含噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂、制备方法及用途
CN106279135A (zh) * 2016-08-09 2017-01-04 浙江医药高等专科学校 一种噻吩磺酰胺结构的苯并喹唑啉类酪氨酸激酶抑制剂
CN106397401B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种抗癌药物的晶体化合物及其制备方法
CN106478598B (zh) * 2016-08-30 2018-11-13 山东罗欣药业集团股份有限公司 一种凡德他尼水合物晶体及其制备方法
AU2017321973B2 (en) 2016-09-02 2024-09-05 Dana-Farber Cancer Institute, Inc. Composition and methods of treating B cell disorders
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
ES2906439T3 (es) 2016-12-05 2022-04-18 Apros Therapeutics Inc Compuestos de pirimidina que contienen grupos ácidos
CN116606261A (zh) 2016-12-22 2023-08-18 美国安进公司 Kras g12c抑制剂及其使用方法
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
WO2019023316A1 (en) 2017-07-26 2019-01-31 Sutro Biopharma, Inc. METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
AU2018329920B2 (en) 2017-09-08 2022-12-01 Amgen Inc. Inhibitors of KRAS G12C and methods of using the same
US12071477B2 (en) 2017-09-18 2024-08-27 Sutro Biopharma, Inc. Anti-folate receptor alpha antibody conjugated with hemiasterlins
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
JP7266043B2 (ja) 2018-05-04 2023-04-27 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法
MA52496A (fr) 2018-05-04 2021-03-10 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
AU2019265822B2 (en) 2018-05-10 2024-07-18 Amgen Inc. KRAS G12C inhibitors for the treatment of cancer
MA52765A (fr) 2018-06-01 2021-04-14 Amgen Inc Inhibiteurs de kras g12c et leurs procédés d'utilisation
WO2019236496A1 (en) 2018-06-04 2019-12-12 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups useful to treat diseases connected to the modulation of tlr7
WO2019241157A1 (en) 2018-06-11 2019-12-19 Amgen Inc. Kras g12c inhibitors for treating cancer
EP3807276A2 (en) 2018-06-12 2021-04-21 Amgen Inc. Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
EP3852811A1 (en) 2018-09-17 2021-07-28 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
JP7516029B2 (ja) 2018-11-16 2024-07-16 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤化合物の重要な中間体の改良合成法
JP7454572B2 (ja) 2018-11-19 2024-03-22 アムジエン・インコーポレーテツド Ｋｒａｓ ｇ１２ｃ阻害剤及びその使用方法
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
JP2022513971A (ja) 2018-12-20 2022-02-09 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド
AU2019403488A1 (en) 2018-12-20 2021-06-24 Amgen Inc. KIF18A inhibitors
AU2019403486A1 (en) 2018-12-20 2021-06-24 Amgen Inc. KIF18A inhibitors
AU2019404576A1 (en) 2018-12-20 2021-06-24 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
WO2020180770A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heterocyclyl compounds and uses thereof
CN113767100A (zh) 2019-03-01 2021-12-07 锐新医药公司 双环杂芳基化合物及其用途
EP3962951A1 (en) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma antibody conjugates
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
MX2021014126A (es) 2019-05-21 2022-01-04 Amgen Inc Formas en estado solido.
CA3146693A1 (en) 2019-08-02 2021-02-11 Amgen Inc. Kif18a inhibitors
US20220372018A1 (en) 2019-08-02 2022-11-24 Amgen Inc. Kif18a inhibitors
AU2020324963A1 (en) 2019-08-02 2022-02-24 Amgen Inc. KIF18A inhibitors
CN114401953A (zh) 2019-08-02 2022-04-26 美国安进公司 Kif18a抑制剂
KR20220054840A (ko) 2019-08-31 2022-05-03 이턴 바이오파마 (상하이) 코., 엘티디. Fgfr 억제제용 피라졸류 유도체 및 이의 제조방법
US20240190862A1 (en) 2019-10-24 2024-06-13 Amgen Inc. Epoxyamides as kras g12c and kras g12d inhibitors and methods of using the same
US11566007B2 (en) 2019-11-04 2023-01-31 Revolution Medicines, Inc. Ras inhibitors
AU2020377925A1 (en) 2019-11-04 2022-05-05 Revolution Medicines, Inc. Ras inhibitors
TW202132315A (zh) 2019-11-04 2021-09-01 美商銳新醫藥公司 Ras 抑制劑
MX2022005525A (es) 2019-11-08 2022-06-08 Revolution Medicines Inc Compuestos de heteroarilo bicíclicos y usos de estos.
TW202132296A (zh) 2019-11-14 2021-09-01 美商安進公司 Ｋｒａｓ ｇ１２ｃ抑制劑化合物之改善的合成
AU2020383535A1 (en) 2019-11-14 2022-05-05 Amgen Inc. Improved synthesis of KRAS G12C inhibitor compound
EP4065231A1 (en) 2019-11-27 2022-10-05 Revolution Medicines, Inc. Covalent ras inhibitors and uses thereof
EP4087611A1 (en) 2020-01-07 2022-11-16 Revolution Medicines, Inc. Shp2 inhibitor dosing and methods of treating cancer
US20230095053A1 (en) 2020-03-03 2023-03-30 Sutro Biopharma, Inc. Antibodies comprising site-specific glutamine tags, methods of their preparation and methods of their use
CA3183032A1 (en) 2020-06-18 2021-12-23 Mallika Singh Methods for delaying, preventing, and treating acquired resistance to ras inhibitors
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers
IL301298A (en) 2020-09-15 2023-05-01 Revolution Medicines Inc Indole derivatives as RAS inhibitors in cancer therapy
US20240051956A1 (en) 2020-12-22 2024-02-15 Qilu Regor Therapeutics Inc. Sos1 inhibitors and uses thereof
CN117616031A (zh) 2021-05-05 2024-02-27 锐新医药公司 用于治疗癌症的ras抑制剂
TW202309052A (zh) 2021-05-05 2023-03-01 美商銳新醫藥公司 Ｒａｓ抑制劑
JP2024516450A (ja) 2021-05-05 2024-04-15 レボリューション メディシンズ インコーポレイテッド 共有結合性ｒａｓ阻害剤及びその使用
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
WO2023114954A1 (en) 2021-12-17 2023-06-22 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
WO2023167560A1 (ko) 2022-03-04 2023-09-07 주식회사 파노로스바이오사이언스 Vegf-grab 및 pd-1 또는 pd-l1 길항제를 포함하는 병용 투여용 조성물
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
TW202408589A (zh) 2022-06-30 2024-03-01 美商舒卓生物製藥公司 抗ror1抗體及抗體結合物、包含抗ror1抗體或抗體結合物之組合物，及製造及使用抗ror1抗體及抗體結合物之方法
WO2024081916A1 (en) 2022-10-14 2024-04-18 Black Diamond Therapeutics, Inc. Methods of treating cancers using isoquinoline or 6-aza-quinoline derivatives
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
US20240352036A1 (en) 2023-04-14 2024-10-24 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
WO2024216048A1 (en) 2023-04-14 2024-10-17 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof

Family Cites Families (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3266990A (en) 1963-09-24 1966-08-16 Warner Lambert Pharmaceutical Derivatives of quinazoline
US3870725A (en) 1971-03-30 1975-03-11 Lilly Industries Ltd Nitrothiazole derivatives
JPS542327A (en) 1977-06-07 1979-01-09 Sankyo Co Ltd Agricultural and horticultural pesticide
JPS5538325A (en) 1978-09-11 1980-03-17 Sankyo Co Ltd 4-anilinoquinazoline derivative and its preparation
US4343940A (en) 1979-02-13 1982-08-10 Mead Johnson & Company Anti-tumor quinazoline compounds
GB2160201B (en) 1984-06-14 1988-05-11 Wyeth John & Brother Ltd Quinazoline and cinnoline derivatives
IL81307A0 (en) 1986-01-23 1987-08-31 Union Carbide Agricult Method for reducing moisture loss from plants and increasing crop yield utilizing nitrogen containing heterocyclic compounds and some novel polysubstituted pyridine derivatives
DE68917485T2 (de) 1988-01-23 1995-02-09 Kyowa Hakko Kogyo Kk Pyridazinon-Derivate und diese enthaltende pharmazeutische Zubereitungen.
US5411963A (en) 1988-01-29 1995-05-02 Dowelanco Quinazoline derivatives
IL89029A (en) 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
DE69202243T2 (de) 1991-02-20 1995-08-31 Pfizer 2,4-Diaminochinazolin-Derivate, um die Antitumorwirkung zu erhöhen.
IL101291A0 (en) 1991-03-22 1992-11-15 Nippon Soda Co 2-pyridine derivatives,their preparation and their use as fungicides
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
US5714493A (en) 1991-05-10 1998-02-03 Rhone-Poulenc Rorer Pharmaceuticals, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
DE4208254A1 (de) 1992-03-14 1993-09-16 Hoechst Ag Substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung als schaedlingsbekaempfungsmittel und fungizid
US5270466A (en) 1992-06-11 1993-12-14 American Cyanamid Company Substituted quinazoline fungicidal agents
US6177401B1 (en) 1992-11-13 2001-01-23 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5712395A (en) 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
GB9314884D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Tricyclic derivatives
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5661147A (en) 1993-09-03 1997-08-26 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
JPH07126165A (ja) 1993-10-29 1995-05-16 Masao Oguro 腫瘍治療剤
US5656643A (en) 1993-11-08 1997-08-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
KR100225721B1 (ko) 1994-02-23 1999-10-15 디. 제이. 우드, 스피겔 알렌 제이 4-헤테로사이클릴-치환된 퀴나졸린 유도체, 이들의 제조 방법 및항암제로서의 용도
WO1995024190A2 (en) 1994-03-07 1995-09-14 Sugen, Inc. Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
ATE159257T1 (de) 1994-05-03 1997-11-15 Ciba Geigy Ag Pyrrolopyrimidinderivate mit antiproliferativer wirkung
DE19503151A1 (de) 1995-02-01 1996-08-08 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
TW414798B (en) 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
TW321649B (hu) 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
AU5108196A (en) 1995-03-20 1996-10-08 Dr. Karl Thomae Gmbh Imidazoquinazolines, drugs containing these compounds, their use and process for their preparation
IL117620A0 (en) 1995-03-27 1996-07-23 Fujisawa Pharmaceutical Co Heterocyclic compounds processes for the preparation thereof and pharmaceutical compositions containing the same
DE122005000053I2 (de) 1995-03-30 2008-01-17 Pfizer Prod Inc Chinazolinderivate
ATE195123T1 (de) 1995-04-03 2000-08-15 Novartis Erfind Verwalt Gmbh Pyrazolderivate und verfahren zu deren herstellung
AU5343096A (en) 1995-04-27 1996-11-18 Zeneca Limited Quinazoline derivatives
GB9508535D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
CA2194756A1 (en) 1995-05-12 1996-11-14 Jun Yuan Novel deazapurine derivatives; a new class of crf1 specific ligands
TW334434B (en) 1995-05-16 1998-06-21 Kanebo Ltd Novel quinazoline compound and anti-tumor agent
US5639757A (en) 1995-05-23 1997-06-17 Pfizer Inc. 4-aminopyrrolo[2,3-d]pyrimidines as tyrosine kinase inhibitors
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5650415A (en) 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
CA2222545A1 (en) 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines and pharmaceutical compositions
ES2203642T3 (es) 1995-06-07 2004-04-16 Pfizer Inc. Derivados de pirimidina heterociclicos con anillos condensados.
US5773459A (en) 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
MX9800215A (es) 1995-07-06 1998-03-31 Novartis Ag Pirrolopirimidas y procesos para su preparacion.
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
UA57002C2 (uk) 1995-10-13 2003-06-16 Мерк Фросст Кенада Енд Ко./Мерк Фросст Кенада Енд Сі. Похідне (метилсульфоніл)феніл-2-(5н)-фуранону, фармацевтична композиція та спосіб лікування
WO1997016435A1 (en) 1995-10-30 1997-05-09 Merck Frosst Canada Inc. 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to cox-2 inhibitors
US6143764A (en) 1995-11-07 2000-11-07 Kirin Beer Kabushiki Kaisha Quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation and pharmaceutical compositions containing the same
DE69613211T2 (de) 1995-11-14 2001-11-15 Pharmacia & Upjohn S.P.A., Mailand/Milano Aryl- und heteroaryl- purin- und pyridopyrimidin- derivate
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
NZ330868A (en) * 1996-02-13 2000-01-28 Zeneca Ltd 4-phenoxy, phenylthio or phenylamino substituted quinazoline derivatives ane medicaments useful as VEGF inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
ES2169355T3 (es) 1996-03-05 2002-07-01 Astrazeneca Ab Derivados de 4-anilinoquinazolina.
DE19629652A1 (de) 1996-03-06 1998-01-29 Thomae Gmbh Dr K 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19608631A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K 4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arnzeimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19608653A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido[5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
AU2103097A (en) 1996-03-15 1997-10-10 Zeneca Limited Cinnoline derivatives and use as medicine
WO1997037999A1 (en) 1996-04-04 1997-10-16 University Of Nebraska Board Of Regents Synthetic triple helix-forming compounds
RO121900B1 (ro) 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
GB9607729D0 (en) 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
DE19614718A1 (de) 1996-04-15 1997-10-16 Hoechst Schering Agrevo Gmbh Substituierte Pyridine/Pyrimidine, Verfahren zu ihrer Herstellung, und ihre Verwendung als Schädlingsbekämpfungsmittel
GB9707800D0 (en) 1996-05-06 1997-06-04 Zeneca Ltd Chemical compounds
GB9613021D0 (en) 1996-06-21 1996-08-28 Pharmacia Spa Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors
DE69734513T2 (de) 1996-06-24 2006-07-27 Pfizer Inc. Phenylamino-substituierte tricyclische derivate zur behandlung hyperproliferativer krankheiten
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
ES2191187T3 (es) 1996-07-13 2003-09-01 Glaxo Group Ltd Compuestos heteroaromaticos biciclicos como inhibidores de la proteina tirosin-quinasa.
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
JP4242928B2 (ja) 1996-08-23 2009-03-25 ノバルティス アクチエンゲゼルシャフト 置換ピロロピリミジンおよびその製造方法
AU4342997A (en) 1996-09-13 1998-04-02 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the reatment of hyperproliferative skin disorders
US6809097B1 (en) 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
NZ330571A (en) 1996-10-01 1999-10-28 Kyowa Hakko Kogyo Kk Nitrogenous heterocyclic compounds that may contain sulphur or oxygen
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
IL129825A0 (en) 1996-11-27 2000-02-29 Pfizer Fused bicyclic pyrimidine derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US5929080A (en) 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
WO1998050038A1 (en) 1997-05-06 1998-11-12 American Cyanamid Company Use of quinazoline compounds for the treatment of polycystic kidney disease
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
AR016817A1 (es) 1997-08-14 2001-08-01 Smithkline Beecham Plc Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento
EP1005470B1 (en) 1997-08-22 2007-08-01 AstraZeneca AB Oxindolylquinazoline derivatives as angiogenesis inhibitors
DE19742379C1 (de) * 1997-09-25 1999-02-11 Siemens Ag Verfahren zum Betrieb eines Ultraschall-Therapiegeräts sowie entsprechendes Gerät
US7262201B1 (en) 1998-10-08 2007-08-28 Astrazeneca Ab Quinazoline derivatives
ATE482946T1 (de) * 1999-02-10 2010-10-15 Astrazeneca Ab Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
US20030086924A1 (en) * 1999-06-25 2003-05-08 Genentech, Inc. Treatment with anti-ErbB2 antibodies
ATE398120T1 (de) 1999-11-05 2008-07-15 Astrazeneca Ab Neue quinazolin-derivate
AU2001235804A1 (en) 2000-03-06 2001-09-17 Astrazeneca Ab Therapy
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
ATE334973T1 (de) 2000-04-07 2006-08-15 Astrazeneca Ab Chinazolinverbindungen
EP1313726A1 (en) 2000-08-09 2003-05-28 AstraZeneca AB Quinoline derivatives having vegf inhibiting activity
CA2415022A1 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Cinnoline compounds
WO2002012227A2 (en) 2000-08-09 2002-02-14 Astrazeneca Ab Indole, azaindole and indazole derivatives having vegf inhibiting activity
GB0126879D0 (en) 2001-11-08 2002-01-02 Astrazeneca Ab Combination therapy
NZ534171A (en) 2002-02-01 2007-06-29 Astrazeneca Ab Quinazoline compounds for the treatment of diseases associated with angiogenesis and/or increased vascular permeability
GB0218526D0 (en) 2002-08-09 2002-09-18 Astrazeneca Ab Combination therapy
WO2004014383A1 (en) 2002-08-09 2004-02-19 Astrazeneca Ab Combination of zd6474, an inhibitor of the vascular endothelial growth factor receptor, with radiotherapy in the treatment of cancer
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
CA2514227C (en) 2003-02-13 2011-08-09 Astrazeneca Ab Combination therapy of zd6474 with 5-fu or/and cpt-11

Also Published As

Publication number Publication date
IS2556B (is) 2009-10-15
CN100376567C (zh) 2008-03-26
CY1108256T1 (el) 2014-02-12
HK1092804A1 (en) 2007-02-16
IL149034A0 (en) 2002-11-10
IS2284B (is) 2007-09-15
KR20080023270A (ko) 2008-03-12
CZ20021526A3 (cs) 2002-07-17
UA72946C2 (uk) 2005-05-16
US10457664B2 (en) 2019-10-29
EP1244647B1 (en) 2006-06-21
NO322298B1 (no) 2006-09-11
WO2001032651A1 (en) 2001-05-10
KR100881105B1 (ko) 2009-02-02
BG65861B1 (bg) 2010-03-31
DK1244647T3 (da) 2006-09-25
AR033499A1 (es) 2003-12-26
ATE330954T1 (de) 2006-07-15
BRPI0015203B1 (pt) 2019-03-26
EP1676845A1 (en) 2006-07-05
SI1244647T1 (sl) 2006-10-31
PT1244647E (pt) 2006-10-31
JP2003513089A (ja) 2003-04-08
US20200262811A1 (en) 2020-08-20
HK1049664A1 (en) 2003-05-23
KR100881104B1 (ko) 2009-01-30
SI1676845T1 (sl) 2008-10-31
TWI287540B (en) 2007-10-01
NO2012014I2 (hu) 2013-09-02
IS8673A (is) 2007-09-04
DE60039206D1 (de) 2008-07-24
US20210276972A1 (en) 2021-09-09
AU769222B2 (en) 2004-01-22
MXPA02004366A (es) 2002-11-07
PT1676845E (pt) 2008-08-05
FR12C0048I1 (hu) 2012-09-14
KR20070104683A (ko) 2007-10-26
PL355942A1 (en) 2004-05-31
US20160130249A1 (en) 2016-05-12
KR20020057996A (ko) 2002-07-12
ES2306306T3 (es) 2008-11-01
US9040548B2 (en) 2015-05-26
BG106659A (bg) 2003-03-31
CZ301689B6 (cs) 2010-05-26
EE200200237A (et) 2003-06-16
HU229414B1 (hu) 2013-12-30
US20070265286A1 (en) 2007-11-15
NO20022139D0 (no) 2002-05-03
HUP0203453A2 (en) 2003-05-28
ZA200202775B (en) 2004-02-25
CN101219145A (zh) 2008-07-16
IL149034A (en) 2009-09-01
HUP0203453A3 (en) 2003-07-28
CY2012026I1 (el) 2015-08-05
IS6335A (is) 2002-04-09
BR0015203A (pt) 2002-07-16
FR12C0048I2 (fr) 2013-08-16
CY1106166T1 (el) 2011-06-08
CY2012026I2 (el) 2015-08-05
SK6122002A3 (en) 2003-01-09
US7173038B1 (en) 2007-02-06
JP3522727B2 (ja) 2004-04-26
US20110065736A1 (en) 2011-03-17
DE60029007D1 (de) 2006-08-03
CA2389767A1 (en) 2001-05-10
NZ518028A (en) 2004-03-26
BRPI0015203B8 (pt) 2021-05-25
US20190002433A1 (en) 2019-01-03
KR100849151B1 (ko) 2008-07-30
NO20022139L (no) 2002-05-03
AU1288601A (en) 2001-05-14
PL203782B1 (pl) 2009-11-30
US20180099946A1 (en) 2018-04-12
SK287401B6 (sk) 2010-09-07
HK1049664B (zh) 2006-11-10
CN1387527A (zh) 2002-12-25
DE60029007T2 (de) 2007-01-11
DK1676845T3 (da) 2008-09-15
NO2012014I1 (no) 2012-08-20
ES2265998T3 (es) 2007-03-01
RU2291868C2 (ru) 2007-01-20
LU92057I2 (fr) 2012-10-08
EP1676845B1 (en) 2008-06-11
US20140121228A1 (en) 2014-05-01
EP1244647A1 (en) 2002-10-02
US8642608B2 (en) 2014-02-04
CA2389767C (en) 2010-03-23
ATE398120T1 (de) 2008-07-15
EE05330B1 (et) 2010-08-16

Similar Documents

Publication Publication Date Title
BE2018C020I2 (hu)
BE2015C057I2 (hu)
BE2016C007I2 (hu)
BE2015C018I2 (hu)
BE2014C017I2 (hu)
BE2013C051I2 (hu)
BE2013C020I2 (hu)
BE2013C015I2 (hu)
BE2013C001I2 (hu)
BE2012C036I2 (hu)
BE2011C004I2 (hu)
BE2008C046I2 (hu)
BE1025464I2 (hu)
BE2010C011I2 (hu)
BRPI0017527B8 (hu)
BE2008C047I2 (hu)
BRPI0001672A2 (hu)
JP2002502666A5 (hu)
BRPI0001542A2 (hu)
JP2002516217A5 (hu)
BRPI0012675B8 (hu)
BRPI0017522A2 (hu)
BRMU7902607U2 (hu)
CN3097870S (hu)
CN3099876S (hu)